FDA Approves Zurnai and Neffy
The benefits of different screening strategies and therapeutic interventions.
The push comes after a letter carrier died after working without air conditioning in 95° weather.
The FDA requested additional trial data, with researchers eager to continue psychedelic trials.
High-cost claims are defined as the top 5% of medical payments within 36 months of injury.
Stop by our educational session or visit our booth for the latest issue of RxInformer magazine.
The FDA issued notices for certain migraine, acetaminophen, clonazepam, and semaglutide products.
Comorbid obesity can complicate recovery, and new drugs create new pharmacy considerations.
The U.S. Department of Labor proposed new rules, while other states introduce legislation.
Behavioral health services represented 8% of total medical payments.
Risk & Insurance magazine reviews the function and value of workers’ comp PBMs – including thoughts from Healthe leaders.
Healthe Clinical experts, Silvia Sacalis and Amanda Waltemath, will speak at the Montana Governor’s Conference on Workers’ Compensation.
Dermatologicals made up the largest share of drug payments, with NSAIDs coming in second.
What is the place of these costly medications in workers’ comp?
Approximately 741 injured workers died of opioid overdose deaths in Massachusetts.
A new bill would give providers more discretion in what medical conditions could qualify a patient for medical cannabis.
Five treatment centers would offer psychedelic therapy for veterans and former first responders.
Adjusters Assemble! Visit Healthe at Booth #921 to learn how we reduce day-to-day burdens for claims professionals.
Notable trends include a decrease in opioid utilization, generic substitution for Lyrica, and increased topical spend.
An increase in the teen workforce could impact workplace injury and claims management.
As another state considers protections, WCRI publishes new data on heat’s impact on workplace accidents.
Oklahoma and Rhode Island enact new presumptions, with Georgia adding extra coverage.
A Maryland taskforce will plan regulation, while Arizona will tentatively cover MDMA treatment for first responders with PTSD.
New data from Quest Diagnostics 2024 Drug Testing Index, and industry leaders discuss how rescheduling will impact workers’ comp.
A new naloxone nasal spray will soon be available.
Identifying and combating a multifaceted problem, including proven and developing strategies.
A total of 14 different reports examine workers’ comp system performance across 17 states from 2017-2022.
While bureaucratic wheels may take time, marijuana will become a Schedule III drug soon.
Healthe’s VP of Clinical Services, Silvia Sacalis, will co-present this educational session at PRIMA 2024.
Patients taking this muscle relaxant may be impacted by a lot from Eugia US/AuroMedics Pharma.
As firefighters see more presumptions for heart disease, keeping track of heart medications could grow in importance.
Visit Healthe at RISKWORLD® 2024 at Booth #1833 for your copy or download a copy now.
If enacted, Senate Bill 2900 would require worker protections from extreme heat and cold.
Different types of cancers are being added to pre-existing presumptions.
Pick up a copy of the new Summer 2024 edition of RxInformer magazine, and learn how Healthe is transforming healthcare.
Simlandi injection was approved for arthritic conditions, while Namzaric receives its first generic approval.
As the market grows, it becomes necessary to understand efficacy, costs, and alternatives.
Tenure more than age and other factors had a higher association with cumulative trauma claims.
California, Georgia, New York, Oklahoma, and Pennsylvania could start a national trend.
Connecticut, Missouri, and New Hampshire join 10 other states considering psychedelics bills.
Amanda Waltemath, Director of Clinical Services joins a panel discussion on April 10th, and Tate Rice, Director of Product Management speaks to Risk & Insurance.
While no clear link is established to these obesity and diabetes drugs, the FDA will continue to monitor data.
This sixth annual survey report highlights the top challenges and priorities of 500 industry professionals.
The rule clarifies differences between employees and contractors, establishing who is entitled to benefits – including workers’ comp.
States so far include Alaska, Arizona, California, Hawaii, Indiana, Illinois, Massachusetts, Maryland, New Jersey, and Wisconsin.
The AvertD test is intended to be used prior to first exposure to oral opioids in patients considered for a 4-30 day prescription for acute pain.
With many federal agencies in alignment, the ultimate decision rests with the DEA.
The growing demand for this drug has led individuals to search for semaglutide from alternative sources.
Injuries accompanied by mental health disorders can increase claim costs and delay recovery.
Many states passed or proposed changes in 2023, with two states so far working on bills for 2024.
A recent proclamation applies to simple federal possession charges on or before December 22, 2023.
As legislative sessions open, several states have continued to introduce PTSD bills.
Healthe’s VP of Clinical Services, Silvia Sacalis, will co-present at the 20th Annual Workers’ Compensation Insurance ExecuSummit.
Hypersensitivity reactions may start as a rash but can quickly result in injury to internal organs.
As opioid utilization decreases, other pharmacy trends bear watching.
A new WCRI report utilizes data from 68,850 workers from 2017-2021.
Employers reported 2.8 million nonfatal workplace injuries and illnesses in 2022, an increase of 7.5% from 2021.
The order seeks increased transparency from AI companies regarding model operations, safety and privacy standards, and consumer/worker protections.
Healthe expertise is featured in Risk & Insurance magazine, both on larger industry trends, and on evolving drug trends.
The acetaminophen and ibuprofen combination was approved for IV use, and as an adjunct to opioid therapy for the treatment of pain.
